Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Genzyme,GelTex form 50-50 JV to market RenaGel; terminated

08 Sep 2004

Executive Summary

GelTex (polymer-based therapeutics) and Genzyme are forming a 50-50 joint venture RenaGel LLC to develop and commercialize GelTex's RenaGel, a treatment for chronic kidney failure patients.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • Joint Venture

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By